UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) February 1, 2023

GE HEALTHCARE TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

	Delaware	001-41528	88-2515116
	(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
	500 W. Monroe Street Chicago, IL		60661
	(Address of principal executive offices)		(Zip Code)
	(Registrant's telep	ohone number, including area code) <u>(</u>	617 <u>)</u> 443-3400
	(Former name	or former address, if changed since l	ast report.)
	ropriate box below if the Form 8-K filing is intende e General Instructions A2. below):	d to simultaneously satisfy the filing o	bligation of the registrant under any of the following
□ Soliciting□ Pre-comr	ommunications pursuant to Rule 425 under the Se material pursuant to Rule 14a-12 under the Excha nencement communications pursuant to Rule 14 nencement communications pursuant to Rule 13	ange Act (17 CFR 240.14a-12) d-2(b) under the Exchange Act (17 CFf	· //
Securities reg	stered pursuant to Section 12(b) of the Act:		
Securities reg	stered pursuant to Section 12(b) of the Act: Title of each class	Trading Symbol(s)	Name of each exchange on which registered
	. ,	Trading Symbol(s)	Name of each exchange on which registered The Nasdaq Stock Market LLC
Com	Title of each class mon stock, par value \$0.01 per share	G⊞C	

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Founders Grants

The Talent, Culture, and Compensation Committee (the "Committee") of the Board of Directors of GE HealthCare Technologies Inc. (the "Company") approved the grant of one-time equity awards (the "Founders Grants") on February 1, 2023 to approximately 8,200 leaders of the Company, including the Company's chief executive officer ("CEO") and the Company's named executive officers who are currently employed by the Company ("NEOs"), in recognition of the pivotal role leadership will play at a critical time following the Company's spin-off as a standalone public company.

The Founders Grants were in the form of restricted stock units ("RSUs") pursuant to the GE HealthCare Founders Restricted Stock Unit Grant Agreement and non-qualified stock options ("Options") pursuant to the GE HealthCare Founders Stock Option Grant Agreement, in each case under the Company's 2023 Long-Term Incentive Plan.

The Founders Grants will vest over a three-year period, with 50% vesting on February 1, 2025 and 50% vesting on February 1, 2026 if the grantee remains employed on the applicable vesting date, with limited exceptions for terminations due to death, disability, or a transfer to a successor employer in connection with the transfer of a business operation by the Company. Unvested RSUs and Options will be forfeited in the event of any other termination of employment, including retirement. Vested Options are exercisable after termination of employment (other than a termination for cause) until the earlier of ninety (90) days following termination of employment or the Option expiration date of February 1, 2033.

For the approximately 700 recipients who regularly receive equity grants as part of their ongoing compensation, including our executive officers, the Founders Grants were consistently applied based on a percentage of annual LTI target. For the approximately 7,500 recipients who do not regularly receive equity grants as part of their ongoing compensation, the Founders Grants were consistently applied based on a percentage of salary. Specifically, the Founders Grants made to the CEO and NEOs were as follows:

<u>Executive</u>	Number of RSUs	Number of Options
Peter J. Arduini	21,425	188,127
Helmut Zodl	5,356	47,031
Jan Makela	4,910	43,112

These descriptions of the terms of the GE HealthCare Founders Restricted Stock Unit Grant Agreement and the GE HealthCare Founders Stock Option Grant Agreement set forth under this Item 5.02, including the addendum to each of these agreements, are qualified in their entirety by reference to the full text of the agreements, which are filed as Exhibits 10.1, 10.2, and 10.3, respectively, to this Current Report on Form 8-K, and are incorporated herein by reference.

One GE HealthCare Annual Bonus Plan

The Committee adopted the One GE HealthCare Annual Bonus Plan (the "Bonus Plan") on February 2, 2023 to provide annual cash incentive opportunities to the Company's executive officers and other employees. The Committee will establish targets for awards to executive officers under the Bonus Plan designed to drive Company, segment, region, and individual performance, as applicable, based on the Company's financial, strategic, and operational priorities.

This description of the terms of the Bonus Plan set forth under this Item 5.02 is qualified in its entirety by reference to the full text of the Bonus Plan, which is filed as Exhibit 10.4 to this Current Report on Form 8-K, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits	
<u>Exhibit</u>	<u>Description</u>
10.1	GE HealthCare Founders Restricted Stock Unit Grant Agreement.
10.2	GE HealthCare Founders Stock Option Grant Agreement.
10.3	Global Addendum to GE HealthCare Founders Restricted Stock Unit Grant Agreement and GE HealthCare Founders Stock Option Grant Agreement.
10.4	One GE HealthCare Annual Bonus Plan.
104	The cover page of this Current Report on Form 8-K formatted in Inline XBRI

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934	, the registrant has duly	caused this report to be signed	d on its behalf by the
undersigned hereunto duly authorized.			

GE HealthCare Technologies Inc.

(Registrant)

Date: February 3, 2023 /s/ Frank R. Jimenez

Frank R. Jimenez, General Counsel and Corporate Secretary (authorized signatory)